Adverum Biotechnologies IncNASDAQ:ADVM
- LAST PRICE7.6400
- TODAY'S CHANGE (%)-0.1200 (-1.5464%)
- Bid / Lots7.6500/ 1
- Ask / Lots7.6800/ 8
- Open / Previous Close7.7900 / 7.7600
- Day Range
- 52 Week Range
- Volume85,094
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADVM |
|---|---|---|
| 09:32 ET | 2075 | 7.79 |
| 09:35 ET | 114 | 7.82 |
| 09:42 ET | 700 | 7.84 |
| 09:50 ET | 100 | 7.815 |
| 09:53 ET | 1821 | 7.82 |
| 09:55 ET | 1432 | 7.82 |
| 10:00 ET | 200 | 7.8 |
| 10:02 ET | 100 | 7.78 |
| 10:08 ET | 1113 | 7.785 |
| 10:09 ET | 200 | 7.83 |
| 10:11 ET | 2870 | 7.82 |
| 10:18 ET | 100 | 7.82 |
| 10:20 ET | 100 | 7.82 |
| 10:22 ET | 100 | 7.835 |
| 10:24 ET | 455 | 7.88 |
| 10:27 ET | 200 | 7.88 |
| 10:36 ET | 1105 | 7.94 |
| 10:38 ET | 100 | 7.97 |
| 10:40 ET | 300 | 7.94 |
| 10:42 ET | 200 | 7.92 |
| 10:44 ET | 200 | 7.92 |
| 10:45 ET | 200 | 7.91 |
| 10:47 ET | 1600 | 7.835 |
| 10:49 ET | 2583 | 7.85 |
| 10:56 ET | 2600 | 7.81 |
| 10:58 ET | 239 | 7.825 |
| 11:02 ET | 2870 | 7.775 |
| 11:03 ET | 500 | 7.77 |
| 11:07 ET | 200 | 7.775 |
| 11:12 ET | 2657 | 7.765 |
| 11:14 ET | 2600 | 7.7744 |
| 11:16 ET | 400 | 7.76 |
| 11:18 ET | 7388 | 7.75 |
| 11:20 ET | 2100 | 7.78 |
| 11:21 ET | 473 | 7.8 |
| 11:32 ET | 300 | 7.81 |
| 11:34 ET | 300 | 7.8 |
| 11:36 ET | 1192 | 7.8 |
| 11:43 ET | 330 | 7.79 |
| 11:45 ET | 200 | 7.77 |
| 11:52 ET | 100 | 7.765 |
| 12:01 ET | 500 | 7.75 |
| 12:06 ET | 1109 | 7.755 |
| 12:08 ET | 678 | 7.76 |
| 12:10 ET | 2198 | 7.765 |
| 12:12 ET | 100 | 7.765 |
| 12:14 ET | 200 | 7.765 |
| 12:19 ET | 200 | 7.765 |
| 12:24 ET | 12815 | 7.735 |
| 12:26 ET | 1520 | 7.735 |
| 12:30 ET | 1000 | 7.72 |
| 12:32 ET | 400 | 7.72 |
| 12:35 ET | 947 | 7.71 |
| 12:37 ET | 200 | 7.7 |
| 12:42 ET | 1048 | 7.69 |
| 12:44 ET | 724 | 7.66 |
| 12:46 ET | 200 | 7.64 |
| 12:48 ET | 2850 | 7.665 |
| 12:50 ET | 186 | 7.64 |
Nov 5, 2024
DJ Adverum Biotechnologies Is Maintained at Sector Perform by RBC Capital, from 11:28AM ET on Tuesday Nov 05, 2024 by Dow Jones
11:28AM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 4, 2024
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones, from 4:39PM ET on Monday Nov 04, 2024 by Dow Jones
4:39PM ET on Monday Nov 04, 2024 by Dow Jones*DJ Adverum Biotechnologies 3Q Loss/Shr $1.30 >ADVM, from 4:39PM ET on Monday Nov 04, 2024 by Dow Jones
4:39PM ET on Monday Nov 04, 2024 by Dow Jones
Oct 16, 2024
Press Release: Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program, from 8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 16, 2024 by Dow JonesAdverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program, from 8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adverum Biotechnologies Inc | 161.4M | -1.3x | --- |
PepGen Inc | 162.6M | -1.6x | --- |
Vaxart Inc | 157.8M | -1.5x | --- |
Skye Bioscience Inc | 166.9M | -1.4x | --- |
Cytodyn Inc | 154.3M | -5.2x | --- |
Generation Bio Co | 145.6M | -1.0x | --- |
Company Information
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Contact Information
- Headquarters
- 100 Cardinal WayREDWOOD CITY, CA, United States 94063
- Phone
- 650-649-1004
- Fax
- 650-329-8151
Executives
- Independent Chairman of the Board
- Patrick Machado
- President, Chief Executive Officer, Director
- Laurent Fischer
- Chief Financial Officer
- Linda Rubinstein
- Chief Operating Officer
- Kishor Soparkar
- Chief Commercial Officer
- Jason Mitchell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $161.4M |
|---|---|
Revenue (TTM) | $1.0M |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.95 |
EPS | $-6.03 |
Book Value | $8.23 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | 161.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -10,310.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
